methyl 2,2-dimethyl-6-{[4-(4-nitrophenyl)-2-quinolyl]oxy}hexanoate | 141746-46-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: methyl 2,2-dimethyl-6-{[4-(4-nitrophenyl)-2-quinolyl]oxy}hexanoate
• 英文别名: methyl 2,2-dimethyl-6-[4-(4-nitrophenyl)quinolin-2-yl]oxyhexanoate
• CAS: 141746-46-5
• 化学式: C₂₄H₂₆N₂O₅
• 分子量: 422.481
• InChiKey: TYXGSFRXKRDXIE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  31
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  94.2
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  methyl 2,2-dimethyl-6-{[4-(4-nitrophenyl)-2-quinolyl]oxy}hexanoate 在 氢氧化钾 、 tin(ll) chloride 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 4.0h， 生成 6-<<4-(4-aminophenyl)-2-quinolyl>oxy>-2,2-dimethylhexanoic acid
  参考文献：
  名称：

  .omega.-[(4-Phenyl-2-quinolyl)oxy]alkanoic acid derivatives: a new family of potent LTB4 antagonists

  摘要：

  A series of omega-[(4-phenyl-2-quinolyl)oxy]alkanoic acid derivatives was prepared which inhibited the binding of the leukotriene B4 to its receptors on guinea pig spleen membranes and on human polymorphonuclear leukocytes. A structure-activity relationship was investigated. The length of the carboxylic acid side chain was important for potent binding activity. The replacement of the oxygen atom at the beginning of the chain with other polar or nonpolar linking groups led to considerable loss of potency, indicating that the oxygen linking atom might be involved in the receptor recognition. Alpha-Substitution on the carboxylic acid side chain led to substantially more potent compounds. Substitution on the phenyl ring and on the quinoline ring was also evaluated.

  DOI：

  10.1021/jm00101a007
• 作为产物：
  描述：

  methyl 6-bromo-2,2-dimethylhexanoate 、 4-(4-nitrophenyl)quinolin-2(1H)-one 在 silver carbonate 作用下， 以 甲苯 为溶剂， 反应 48.0h， 以46%的产率得到methyl 2,2-dimethyl-6-{[4-(4-nitrophenyl)-2-quinolyl]oxy}hexanoate
  参考文献：
  名称：

  .omega.-[(4-Phenyl-2-quinolyl)oxy]alkanoic acid derivatives: a new family of potent LTB4 antagonists

  摘要：

  A series of omega-[(4-phenyl-2-quinolyl)oxy]alkanoic acid derivatives was prepared which inhibited the binding of the leukotriene B4 to its receptors on guinea pig spleen membranes and on human polymorphonuclear leukocytes. A structure-activity relationship was investigated. The length of the carboxylic acid side chain was important for potent binding activity. The replacement of the oxygen atom at the beginning of the chain with other polar or nonpolar linking groups led to considerable loss of potency, indicating that the oxygen linking atom might be involved in the receptor recognition. Alpha-Substitution on the carboxylic acid side chain led to substantially more potent compounds. Substitution on the phenyl ring and on the quinoline ring was also evaluated.

  DOI：

  10.1021/jm00101a007

文献信息

• Substituted bicyclic bis-aryl compounds exhibiting selective leukotriene
  申请人：Rhone-Poulenc Rorer S.A.

  公开号：US05366982A1

  公开（公告）日：1994-11-22

  This invention relates to compounds having selective LTB.sub.4 antagonist properties, compositions comprising said compounds and methods for the treatment of disorders involving LTB.sub.4 agonist-mediated activity utilizing said compositions wherein the compounds are described by the general formula ##STR1## and pharmaceutically acceptable salts thereof.

  本发明涉及具有选择性LTB.sub.4拮抗性的化合物，包括所述化合物的组合物以及利用所述组合物治疗涉及LTB.sub.4激动剂介导活性的疾病的方法，其中所述化合物由一般公式##STR1##和其药用可接受的盐描述。
• SUBSTITUTED BICYCLIC BIS-ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS
  申请人：RHONE-POULENC RORER S.A.

  公开号：EP0540604A1

  公开（公告）日：1993-05-12
• US5366982A
  申请人：——

  公开号：US5366982A

  公开（公告）日：1994-11-22
• US5492915A
  申请人：——

  公开号：US5492915A

  公开（公告）日：1996-02-20
• [EN] SUBSTITUTED BICYCLIC BIS-ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS
  申请人：——

  公开号：WO1992001675A2

  公开（公告）日：1992-02-06

  [FR] L'invention concerne des composés ayant des propriétés antagonistes sélectives sur LTB4 et comprenant un anneau aryle ou hétéroaryle monocyclique ou bicyclique qui possède au moins deux substituants rattachés: (1) un anneau aryle ou hétéroaryle monocyclique ou bicylique substitué ou non substitué et (2) une chaîne de substitution ayant un groupe fonctionnel acide carboxylique terminal ou un dérivé de celui-ci rattaché à la chaîne. Cette invention concerne en outre des procédés pour la préparation de ces composés ainsi que des compositions thérapeutiques comprenant ledit composé, et des procédés pour le traitement de troubles impliquant une activité induite par un antagoniste LTB4 en utilisant lesdites compositions dans lesquelles les composés sont décrits par la formule générale (I) et leurs sels pharmaceutiquement acceptables.